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Abstract
Background: PPARs (a,c,d) are a family of ligand-activated transcription factors that regulate energy balance, including lipid
metabolism. Despite these critical functions, the integration between specific pathways of lipid metabolism and distinct
PPAR responses remains obscure. Previous work has revealed that lipolytic pathways can activate PPARs. Whether hepatic
lipase (HL), an enzyme that regulates VLDL and HDL catabolism, participates in PPAR responses is unknown.
Methods/Principal Findings: Using PPAR ligand binding domain transactivation assays, we found that HL interacted with
triglyceride-rich VLDL (.HDL&LDL, IDL) to activate PPARd preferentially over PPARa or PPARc, an effect dependent on HL
catalytic activity. In cell free ligand displacement assays, VLDL hydrolysis by HL activated PPARd in a VLDL-concentration
dependent manner. Extended further, VLDL stimulation of HL-expressing HUVECs and FAO hepatoma cells increased mRNA
expression of canonical PPARd target genes, including adipocyte differentiation related protein (ADRP), angiopoietin like
protein 4 and pyruvate dehydrogenase kinase-4. HL/VLDL regulated ADRP through a PPRE in the promoter region of this
gene. In vivo, adenoviral-mediated hepatic HL expression in C57BL/6 mice increased hepatic ADRP mRNA levels by 30%. In
ob/ob mice, a model with higher triglycerides than C57BL/6 mice, HL overexpression increased ADRP expression by 70%,
demonstrating the importance of triglyceride substrate for HL-mediated PPARd activation. Global metabolite profiling
identified HL/VLDL released fatty acids including oleic acid and palmitoleic acid that were capable of recapitulating PPARd
activation and ADRP gene regulation in vitro.
Conclusions: These data define a novel pathway involving HL hydrolysis of VLDL that activates PPARd through generation
of specific monounsaturated fatty acids. These data also demonstrate how integrating cell biology with metabolomic
approaches provides insight into specific lipid mediators and pathways of lipid metabolism that regulate transcription.
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Introduction
Peroxisome Proliferator-Activated Receptors (PPARs) are
ligand-activated transcription factors that regulate genes involved
in energy balance [1]. Three PPAR isotypes – alpha (a), beta/
delta (b/d), and gamma (c)- are expressed in metabolically active
tissues as well as vascular and inflammatory cells [2,3]. Genetic
models and studies with synthetic PPAR agonists reveal key but
distinct functions for PPARa and PPARd in regulating fatty acid
(FA) metabolism in muscle and liver, whereas PPARc is a critical
determinant of adipose tissue differentiation [4]. PPAR activation
also modulates inflammatory pathways relevant for atherosclerosis
and type 2 diabetes (T2D) [5–8]. Although various lipid mediators
including long chain FAs, eicosanoids and phospholipids (PLs) are
reported to activate PPARs in vitro, insight into pathways that can
generate endogenous PPAR ligands has been limited [9,10]. In the
absence of such information, it remains difficult to place PPAR
activation and subsequent transcriptional responses into a physio-
logic or pathologic network.
Prior work suggests that lipase-mediated lipoprotein metabolism
can regulate PPAR responses. Both lipoprotein lipase (LPL) and
endothelial lipase (EL) preferentially activate PPARa through
hydrolysis of VLDL and HDL, respectively [11–14]. The specific
LPL and EL-generated metabolites that mediate these responses
have remained unidentified. More recently, hepatic de novo
lipogenesis was reported to produce an endogenous phospholipid
PPARa ligand in murine liver with no effect on PPARd or PPARc
[10]. Since all three PPAR isotypes are expressed in hepatocytes,
the selectivity of de novo lipogenesis for PPARa activation suggests
that other pathways of lipid metabolism in the liver may be
involved in PPARd or PPARc activation.
Hepatic lipase (HL), expressed in hepatocytes as well as
macrophages, is central to lipoprotein metabolism [15–17]. As
both a triacylglycerol hydrolase and phospholipase, HL has been
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FAs as well as other lipid mediators [18]. Murine transgenic and
HL-deficiency models have established that HL regulates HDL
and IDL-cholesterol with modest effects on VLDL triglyceride
(TG) content [19,20]. Humans carrying an HL loss-of-function
mutation manifest elevated TG content in lipoproteins including
VLDL and HDL [21]. Despite these important effects, uncertainty
persists regarding HL’s role in systemic metabolism. Indeed, HL
has been alternatively reported to promote or limit both
atherosclerosis and T2D [22–26]. Transcriptional responses
induced through HL action have not been previously explored.
We postulated that HL hydrolytic activity might be involved in
transcriptional regulation via PPARs, given the role of these FA-
activated nuclear receptors in hepatic responses. We also reasoned
that probing HL’s effects on transcriptional regulation might
provide a new way to consider functional roles of HL in systemic
metabolism. In contrast to EL and LPL, which activate PPARa,
we demonstrate here that HL hydrolyzes VLDL to generate
predominantly PPARd activation. By integrating this data with a
global metabolite profiling approach, we found that VLDL
hydrolysis by HL generates specific unsaturated FAs that can
induce canonical PPARd dependent transcriptional responses in
vitro and in vivo, with functional effects on cellular lipid droplet
formation in hepatocytes. Together these data provide new insight
into HL biology, how PPARd may be activated and an example of
how coupling cell biology with metabolomic methods can identify
specific lipid mediators exerting distinct biologic effects.
Materials and Methods
Ethics statement
All animal experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) and conducted in
agreement with NIH policy (Protocol # 03121).
Reagents
A 1.5 kb human HL cDNA was subcloned into pcDNA3 [18].
The HL catalytic mutant was generated by replacing serine
position 149 with alanine using the Stratagene QuikChange PCR
approach (primers 59-CACCTAATTGGGTACGCCCTGGGT-
GCA-39 and 59CGTGTGCACCCAGGGCGTACCCAATTA-
39), and the mutation was confirmed by DNA sequencing.
Adenovirus HL catalytic mutant was amplified/purified by
Welgen, Inc. (Worcester, MA). Human lipoproteins (VLDL,
HDL) were purchased from Biomedical Technologies, Inc
(Stoughton, MA). LDL was isolated by potassium bromide
density ultracentrifugation [11]. IDL was prepared from plasma
of healthy volunteers as previously described. Lipoprotein
concentrations are normalized to protein in mg/mL and sti-
mulations were performed for each lipoprotein fraction at levels
consistent with the published literature. [23,27–29]. Chemicals
were purchased from: Roche Pharmaceutics (Tetrahydrolipsta-
tin), Alexis Biochemical (GW501516), Cayman Chemical
(WY14643 and all FAs), Sigma-Aldrich (Lipoprotein deficient
serum, triolein, egg phosphatidylcholine and FA-free BSA). The
time-resolved, fluorescence resonance energy transfer (TR-
FRET) PPARd competitive binding assay was performed for
PPARd as per manufacturer protocol (Invitrogen) using a
PerkinElmer Envision fluorescence plate reader. Briefly, a GST
tagged recombinant PPARd-LBD is incubated with a terbium
labeled anti-GST antibody along with a fluorescein labeled
small molecule (synthetic) PPAR ligand. In the absence of
exogenous ligand, the fluorescein labeled PPAR ligand binds to
the PPAR-LBD and FRET occurs between the terbium and
fluorescein fluorophores. In thep r e s e n c eo fa nu n l a b e l e dP P A R
ligand, displacement of the fluorescein PPAR ligand reduces
FRET as measured by the emission ratio of 520 nm/495 nm.
Cell culture
FAO hepatoma cells were maintained in RPMI supplemented
with 10% FBS and antibiotics. HUVEC were cultured in M-199
medium supplemented with 20% fetal bovine serum, endothelial
cell growth factor, 1% heparin and penicillin/streptomycin
antibiotic. Lipoprotein stimulations were done in serum free
medium. Fatty acid-BSA complex was generated by mixing oleic
acid with 10%, fatty acid free BSA (4:1 molar ratio) for 1 hour at
37 degrees.
Cell transfection, reporter assays, siRNA and adenovirus
infection
HEK-293, COS-7 and FAO cells were transfected in a 24 well
plate with each PPAR-ligand binding domain construct (LBD)
using Fugene HD (Roche) as previously described. [12,30]. Briefly,
fusion constructs of the PPAR-LBDs and the yeast GAL4 DNA
binding domain were transfected into cells at 100 ng DNA/well
along with a GAL4 dependent luciferase reporter at 70 ng DNA/
well and the internal control CMV-b galactosidase at 50 ng
DNA/well. Where indicated, cells were also transfected with
human HL, catalytically inactive HL or control vector (pcDNA3)
at 100 ng DNA/well. PPAR ligand activity was quantified by
changes in luciferase reporter gene expression measured by
standard luminometer assay and normalized to b-galactosidase.
ADRP promoter constructs were a gift from Dr. Toshiya Tanaka,
University of Tokyo, Japan [31] and were transfected at 100 ng
DNA/well in a 24 well plate. SiRNA constructs (Ambion) were
transfected using siDeliverX reagent (Panomics) according to
manufacturer’s protocol. For adenovirus experiments, cells were
seeded (1610
6) in 6 well plates and infected for 24 hours with
adenovirus constructs (MOI 100) in 1 mL of serum free medium.
The media was replaced with fresh, serum free media with
indicated concentrations of lipoproteins for 12 hours unless
otherwise indicated.
Mice
Eight-week-old male, C57BL/6 and ob/ob mice were pur-
chased from Jackson Laboratories (Bar Harbor, ME). Animals
were acclimated for 5 days and fed standard chow diet.
Adenovirus was injected by tail vein using 1610
11 virus particle
in 100 mL volume. Five days after injection, mice were euthanized
and whole liver, epididymal fat and quadriceps skeletal muscle
were isolated and snap frozen in liquid nitrogen for RNA isolation.
RNA isolation, reverse transcription and real time PCR
Total cell mRNA was isolated using an RNeasy kit (Qiagen).
For whole liver and skeletal muscle RNA isolation, 30–50
micrograms of tissue were homogenized in RNA lysis buffer
1 mL (Qiagen); epididymal fat from wild type mice and ob/ob
liver RNA isolation was isolated using the RNeasy lipid isolation
kit (Qiagen). Following isolation, 1 microgram of RNA was
digested with DNase I (invitrogen) and reverse transcribed using
QuantiTect kit (Qiagen). Real Time PCR (RT-PCR) was
performed in a MyiQ Single-Color Real Time PCR system using
SYBR Green I (Bio-Rad). The mRNA levels of test genes were
normalized to 36B4 internal control gene. Standard curves were
generated to calculate relative copy number. The primer
sequences used were: Human ADRP: 59-TGAGATGGCA-
GAGAACGGTGTG-39 and 59-GGCATTGGCAACAATCT-
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AC-39 and 59-GTGAGGTCCTCCTTGGTGAA-39; Human
PPARd:5 9-TGGCTTTGTCACCCGTGAGT-39 and 39-ACT-
GAGTTCGCCAAGAGCAT-39;Rat ADRP: 59-GCCTCTCAA-
CTGGCTGGTAG and 59-GCTCAGACTGCTGGACCTTC-
39; Rat 36B4: 59-CACCTTCCCACTGGCTGAA-39 and 59-
TCCTCCGACTCTTCCTTTGC-39; Murine ADRP: 59-CAA-
GTCGGAGCTGCTGGTAG-39 and 59-CCGAGAGCAGAGC-
TTGGTAG-39: Murine 36B4: 59-CAACCCAGCTCTGGAGA-
AAC-39 and 59-GAGGTCCTCCTTGGTGAACA-39.
Western blotting
Transfected cells were lysed in RIPA buffer containing EDTA
and protease inhibitors. Following SDS-PAGE separation, immu-
noblotting was performed using a monoclonal antibody human
HL antibody (Santa Cruz Biotechnology) as described previously
[32]. Human HL western was performed on plasma following a
50-fold dilution in PBS.
HL activity assay
A glycerol-stabilized emulsion of triolein and egg phosphatidyl-
choline containing glycerol-tri[9,10(n)-
3H] oleate was used to
measure HL activity in conditioned media from cells as described
previously [32]. For HL activity in vivo, plasma was collected at
baseline or 30 minutes following heparin injection (intraperitoneal,
200 U); activity assays were performed on 10 microliters of
plasma.
Liquid Chromatography/Mass Spectrometry
For metabolite profiling experiments, COS-7 cells (1610
6) were
infected with adenoviral GFP or HL- expressing constructs for
24 hours in 6 well plates. Cells were treated with heparin 10 U/
mL for 1 hour, followed by stimulation with VLDL at 50 mg/mL
for 6 hours. The cell supernatant was harvested on ice, centrifuged
at 3000 rpm for 5 minutes, transferred to a fresh tube and snap
frozen in liquid nitrogen for subsequent lipid extraction. A 2:1:1
CHCL3/MeOH/conditioned media solution was prepared for
lipid extraction to isolate organic soluble metabolites. A
13C oleic
acid standard was included in these samples for targeted FA
quantification. Following brief vortexing, samples were centrifuged
at 2500 rpm at 4 degrees for 10 minutes. After centrifugation the
organic layer (bottom) was transferred to a new vial and solvents
evaporated under a stream of nitrogen. Samples were resuspended
in CHCL3 (120 mL) and stored at 280 until LC/MS analysis
(within 48 hours of extraction). For both positive and negative
ionization mode LC/MS runs, 30 ml of extract was injected.
LC/MS analysis was performed using an Agilent 6530
Accurate-Mass Quadrupole-TOF LC/MS system. For LC
analysis in negative mode, a Gemini (Phenomenex) C18 column
(5 mm, 4.66100 mm) was used together with a pre-column (C18,
3.5 mm, 2620 mm). Mobile phase A consisted of 95/5 water/
methanol and mobile phase B was composed of 60/35/5
isopropanol/methanol/water. Both A and B were supplemented
with 0.1% ammonium hydroxide. The flow rate for each run was
0.5 mL/min. The gradient started at 0% B and linearly increased
to 100% B over 40 minutes, was then maintained at 100% B for
8 minutes before equilibrating for 8 minutes at 0% B. For the LC
analysis in positive mode, a Luna (Phenomenex) C5 column
(5 mm, 4.66100 mm) was used together with a pre-column (C4,
3.5 mm, 2620 mm). Mobile phase A and B and the gradient were
the same as for negative mode, but supplemented with 0.1%
formic acid and 5 mM ammonium formate. MS analysis was
performed with an electrospray source ionization (ESI) interface.
The capillary voltage was set to 3.0 kV and the fragmentor voltage
to 100 V. The drying gas temperature was 350uC, the drying gas
flow was 10 L/min, and the nebulizer pressure was 45 psi. Data
was collected using a mass range from 100–1200 Da.
Statistical analysis
For luciferase reporter experiments all results were performed in
triplicate and are reported as mean +/2 SD. For RT-PCR, results
are reported as mean +/2 SD. Differences were analyzed by 2
tailed, student’s t test. LC/MS data are presented as mean +/2
SD of the ion intensity area. Results are interpreted as statistically
significant for p value,.05.
Results
Hepatic Lipase uses VLDL preferentially to activate PPARd
Standard PPAR ligand binding domain (LBD) assays for all
three human PPAR isoforms were performed in hepatic lipase
(HL)-transfected 293 cells stimulated with HDL, IDL, LDL and
VLDL at the concentrations shown (normalized to total protein).
With TG-rich VLDL as a substrate, HL activated PPARd
preferentially relative to PPARa or PPARc, with significantly
lesser responses to HDL and even less for LDL and IDL
(VLDL...HDL.LDL, IDL, Fig. 1A). HDL stimulation with
protein concentrations as high as 1 mg/mL, which approximates
circulating Apolipoprotein A1 plasma levels, had no effect on
PPAR activation (Fig. S3). PPARd LBD activation in HL-
expressing cells was evident in a VLDL concentration-dependent
manner (10–50 mg/mL, Fig. 1B). In similar HL-transfected 293
cells, VLDL stimulation also activated a co-transfected canonical
PPAR response element (PPRE) direct repeat luciferase construct
(Fig. 1C). HDL, IDL or LDL stimulation had no effect on the
PPRE-reporter in similar HL-transfected cells (Fig. 1C).
HL/VLDL activation of PPARd requires intact catalytic HL
function
In addition to its lipolytic activity, HL can also promote non-
catalytic lipoprotein transport into cells [33,34]. The role of HL
catalytic function in PPAR activation was investigated in two ways:
using the lipase inhibitor tetrahydrolipstatin and transfection of a
catalytically inactive HL mutant. Tetrahydrolipstatin inhibited
HL/VLDL activation of PPARd in a dose-dependent manner in
293 cells (Fig. 2A). In a complementary approach, we mutated the
catalytic site in human HL by site-directed mutagenesis. This
mutant expressed to a similar degree in cell lysate and media
compared to wild type HL, as determined by western blot (Fig.
S1A), but possessed no enzymatic activity (Fig. S1B). In the
presence of VLDL stimulation, catalytically inactive HL no longer
activated PPARd (Fig. 2B). Together, these data establish HL-
mediated PPARd activation requires HL catalytic function. To
further examine the direct role of HL hydrolysis of VLDL in
generating a PPARd ligand, we performed time-resolved,
fluorescence resonance energy transfer (TR-FRET) PPARd
competitive binding assays with increasing concentrations of
VLDL in the presence of recombinant HL. This cell free assay
measures FRET induced by interaction between a known,
fluorescently labeled synthetic PPARd agonist and recombinant,
fluorescently labeled PPARd LBD. The presence of another
PPARd ligand, in this case one generated by HL-mediated VLDL
hydrolysis, causes competitive displacement of the labeled ligand
resulting in decreased FRET. When tested in this cell free system,
recombinant HL in the presence of VLDL reduced FRET in a
linear, VLDL concentration-dependent manner, consistent with a
concentration-dependent increase in a PPARd ligand (Fig. 2C).
Hepatic Lipase and VLDL Activate PPARd
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e21209Figure 1. Hepatic lipase activates PPARd selectively in the presence of human VLDL. (A) HEK293 cells transfected with human PPARa, c,o r
d ligand binding domain-Gal4 fusion constructs along with the pUAS64TK Gal4 dependent luciferase reporter were stimulated with human VLDL
50 mg/mL, IDL 20 mg/mL, HDL 100 mg/mL or LDL 100 mg/mL for 12 hours. Luciferase values were normalized to b-galactosidase and results expressed
as mean fold change of the normalized luciferase RLU. Each experimental condition was performed in triplicate and results are mean +/2 SD. *p,.05
vs. empty vector. (B) HEK-293 cells were transfected with the PPARd-LBD along with the luciferase reporter above. Cells were stimulated with
indicated concentrations of human, pooled VLDL for 12 hours, then samples harvested for analysis. * p,.05 vs. empty vector. (C) HEK-293 cells were
transfected with a PPRE-Luciferase reporter along with CMV-b-galactosidase and pcDNA or HL. Following transfection cells were stimulated with
VLDL 50 mg/mL, HDL 100 mg/mL or LDL 100 mg/mL as before for 12 hours. *p,.05 vs. pcDNA.
doi:10.1371/journal.pone.0021209.g001
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generate a PPARd agonist.
HL/VLDL induces expression of ADRP, a canonical PPARd
target gene, in a manner dependent on HL catalysis and
PPARd expression
PPARd regulates genes involved in lipid metabolism. Adipocyte
differentiation-related protein (ADRP), a lipid droplet associated
protein involved in the cellular adaptation to lipid loading, is an
established PPARd target gene [31]. We used primary human
umbilical vein endothelial cells (HUVEC) as a heterologous cell
model that contains PPARd but does not express HL or LPL to
test whether VLDL regulates ADRP gene expression after
adenoviral HL (Ad-HL) versus control GFP (Ad-GFP) infection.
VLDL stimulation (20 mg/mL) of Ad-HL infected HUVECs
increased ADRP mRNA levels ,4 fold but had no effect on Ad-
GFP cells, as assessed by RT-PCR (Fig. 3A). A similar fold change
in ADRP mRNA expression was observed with the PPARd
synthetic agonist GW501516 (1 mM) in HUVECs. In contrast,
adenoviral transfection of a catalytically inactive HL had no effect
on ADRP expression in the presence of VLDL stimulation in this
same HUVEC system (Fig. 3B). To test if HL/VLDL induction of
ADRP was dependent on PPARd, similar experiments were
repeated in the presence of a small interfering PPARd construct
(siPPARd, Fig. S2). ADRP mRNA expression in response to HL/
VLDL stimulation was decreased ,80% in the presence of
siPPARd versus control siRNA (Fig. 3C). Previous work has
identified a functional PPRE in the human ADRP promoter
region (22361 to 22345 bp) [31]. To determine if HL/VLDL
activates ADRP expression through this PPRE, we used a 4 kb
human ADRP promoter-luciferase reporter construct (4 kb
ADRP-Luc) transfected into COS cells. VLDL stimulation of
COS cells expressing HL doubled the activity of the cotransfected
ADRP promoter-Luc reporter; no effect was seen in an ADRP
promoter construct in which the PPRE contained a point
mutation (D1 ADRP-Luc, Fig. 3D).
HL/VLDL regulates PPARd target gene expression in FAO
hepatoma cells in vitro and in murine liver in vivo
Given the data above, we next tested HL regulation of ADRP
expression through PPARd in a hepatocyte-derived model system
in vitro. Rat FAO hepatoma cells were used since primary mouse
hepatocytes lose PPARd expression shortly after isolation (data
not shown). VLDL stimulation of FAO hepatoma cells infected
with Ad-HL significantly increased ADRP mRNA levels in a
VLDL concentration-dependent manner (Fig. 4A). HL hydrolysis
of VLDL also increased expression of angiopoietin like protein-4
(ANGPLT4) and pyruvate dehydrogenase kinase 4 (PDK4), two
known PPARd-regulated genes with important roles in systemic
lipid metabolism (Fig. 4A) [31]. ADRP facilitates storage of
neutral lipids in cytoplasmic lipid droplets. Consistent with this
role, HL/VLDL stimulation increased lipid accumulation in
FAO cells versus control, as measured by Oil Red O staining
(Fig. 4B).
We next investigated evidence for this HL/VLDL/PPARd
pathway in vivo. Although human and murine HL metabolize
similar lipoprotein substrates, murine HL circulates freely in
plasma in mice (.70% of HL activity), whereas human HL is
retained in the liver, bound to heparin sulfate proteoglycans
(HSPGs) on the hepatocyte cell surface [35]. Eight week old
C57BL/6 male mice on standard chow diet were infected with
similar human Ad-GFP or Ad-human HL constructs by tail vein
injection, followed five days later by plasma and tissue harvest for
analysis of human HL protein and activity as well as changes in
gene expression. Human HL mRNA expression was restricted to
the liver and was not detected in skeletal muscle or epididymal fat
(Fig. 4C). HL protein levels and activity in the plasma were also
not different compared to GFP expressing mice at baseline
(Fig. 4C). However, thirty minutes after heparin treatment plasma
HL activity was significantly higher in the human HL-overex-
pressing mice compared with the Ad-GFP injected mice. This
result is consistent with human HL localization to liver HSPGs
and release into plasma by heparin (Fig. 4C). As such, HL
expression by adenoviral infection provides a model to test directly
whether increasing hepatocyte HL expression regulates hepatic
PPARd transcriptional responses in vivo. In this model, ADRP
expression was significantly increased by 30% in livers from the
C57Bl/6 mice receiving HL as compared to GFP (Fig. 4D). ADRP
expression did not differ between HL or GFP in the epididymal fat
or skeletal muscle of these mice (Fig. 4D). As noted, HL is an
important determinant of circulating TG levels. In C57BL/6
mice, TG levels are low on standard chow diet. Adenoviral HL
infection in C57BL/6 mice decreased TG levels from 48 mg/dL
to 28 mg/dL. Given our in vitro data for VLDL, a TG-rich
lipoprotein, serving as the preferred substrate for HL-mediated
PPARd activation, we reasoned that circulating TG levels might
influence HL/VLDL mediated PPARd responses. The ob/ob
mouse develops modestly higher plasma TGs than chow-fed
C57BL/6 mice, but still within the normal range. Six-eight week
old, ob/ob mice were infected with Ad-GFP or Ad-HL. Baseline
TG levels were 70 mg/dL the Ad-GFP group versus 25 mg/dL in
the Ad-HL cohort five days after adenoviral infection. In this ob/
ob model with higher triglycerides compared to the wild-type
mice, hepatic ADRP mRNA levels increased more than in the
C57BL/6 mice (70% vs 30%) following HL overexpression, as
compared to GFP (Fig. 4D, Liver – ob/ob).
VLDL hydrolysis by HL liberates unsaturated FAs that
activate PPAR transcription
HL/VLDL activates PPARd through its catalytic products.
VLDL is a TG-rich lipoprotein, with lower concentrations of PL,
diacylglycerol, monoacylglycerol and cholesterol [36]. To inves-
tigate the role of specific HL/VLDL hydrolytic products in
PPARd activation, a global metabolite profiling approach using
liquid chromatography coupled to mass spectrometry (LC/MS)
was employed [37]. A profiling LC/MS approach can identify
metabolites generated by HL-mediated VLDL hydrolysis in an
unbiased fashion. By coupling this global metabolite profiling
Figure 2. HL/VLDL activation of PPARd depends on catalytic function. (A) HEK-293 cells were transfected with PPARd-LBD and pretreated
with indicated concentrations of tetrahydrolipstatin (THL) or DMSO control for 30 minutes prior to stimulation with VLDL 30 mg/mL for 12 hours.
Results expressed as mean fold change. *p,.05 vs. empty vector. (B) COS-7 cells were transfected with pcDNA, HL or catalytically inactive HL and
stimulated with indicated concentrations of VLDL for 12 hours. *p,.05 vs. pcDNA. **p,.05 versus HL and pcDNA. (C) Time-resolved FRET PPARd
competitive binding assay: Recombinant HL was incubated with increasing concentrations of VLDL (1 mg/mL and 10 mg/mL) for 1 hour with
recombinant GST-PPARd-LBD, terbium-labeled anti-GST antibody and a fluorescein-labeled PPARd synthetic agonist. FRET activity, measured by the
emission ratio of fluorescence at 520 nm/495 nm, was inhibited in a VLDL concentration dependent manner in the presence of HL. The synthetic
PPARd ligand, GW501516, maximally inhibited FRET at 1 mM. *p,.05 compared to VLDL alone.
doi:10.1371/journal.pone.0021209.g002
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ability of specific HL/VLDL metabolites to activate PPARd can
be tested. Further, by using
13C labeled oleic acid as an internal
standard, LC/MS also enables quantification of specific FA
products liberated by HL/VLDL.
As compared to GFP-expressing COS cells, VLDL stimulation
of HL-expressing cells (6 hours) generated statistically significant
increases in levels of specific long chain FA species, as measured by
LC/MS in negative ionization mode (Fig. 5A, left panel). This
platform also affords analysis of relative TG versus PL hydrolysis
by HL with intact lipoprotein substrates. Sample analysis in
positive ionization mode revealed greater reductions of both TG
and diacylglycerol levels relative to PL levels in the HL group,
indicating TG as the major source of HL-generated FA in this
model (Table 1). Other lipids, including cholesterol, cholesterol
esters and sphingomyelin, were unchanged (Table 1).
The fold changes seen in HL- versus GFP-expressing cells for
both saturated and unsaturated FAs were significant, but a
proportionally larger difference in release of monounsaturated and
polyunsaturated FAs was detected, with a particular difference in
palmitoleic (PO - C16:1, 8 fold) and oleic (OA - C18:1, 4.5 fold)
FAs (Fig. 5A, right panel). The fold changes for linoleic (C18:2),
linolenic (C18:3), arachidonic (C20:4), and eicosapentaenoic
(C20:5) were also statistically significant (Fig. 5A, right panel).
We focused on the most abundant FAs identified by metabolite
profiling, PO and OA (15, 80 mM, Fig. 5A, left panel), as well as
the corresponding saturated FAs palmitate (PA, C16:0) and
stearate (SA, C18:0) to determine if the specific HL/VLDL-
induced FA changes detected were relevant for PPARd activation.
Both PA and PO modestly activated PPARd LBD, achieving 25%
LBD activation at 100 mM relative to maximal stimulation with
the potent PPARd selective agonist GW50156. By contrast, OA
activated PPARd in a concentration-dependent fashion, achieving
approximately 70% of maximal GW activation at 100 mM
(Fig. 5B); SA only modestly activated PPARd at the same
concentration. Additionally, the polyunsaturated FAs (C18:2,
C18:3, C20:4, C20:5 and C22:6) demonstrated minimal PPAR
transcriptional activity when used at the concentrations quantified
in metabolite profiling experiments (data not shown). Given
evidence that OA but not SA was released by HL/VLDL
hydrolysis, we next returned to ADRP regulation. We tested if OA
regulates ADRP gene expression in FAO hepatoma cells. OA
stimulation (12 hrs, 100 mM) increased ADRP mRNA expression
two fold, ,70% of the GW501516 response and consistent with
the PPARd LBD assay responses (Fig. 5C).
Discussion
The nuclear receptors PPARa, d and c coordinate carbohy-
drate, lipid, and lipoprotein metabolism. Despite the importance
of these transcription factors in hepatocyte biology, mechanisms of
PPAR activation in the liver remain poorly understood. The data
provided here identifies a new role for hepatic lipase (HL) in PPAR
activation. HL hydrolyzes VLDL to generate predominantly
PPARd activation, with markedly lesser effects on PPARa and
even less on PPARc. Despite HL’s known phospholipase activity,
HDL, the most PL-rich circulating lipoprotein class, was less
effective as a substrate in HL-mediated PPARd activation as
compared to VLDL. IDL remnant lipoprotein exposure to HL
also did not activate PPARd. In support of this novel HL/VLDL/
PPARd pathway, HL/VLDL induced expression of the canonical
PPARd target genes ADRP, ANGPLT4 and PDK4, in HUVECs
and FAO cells, and had functional effects on increased lipid
droplet formation. In keeping with these findings, hepatic
expression of human HL in vivo increased ADRP expression in
C57BL/6 and ob/ob mice. Global metabolite profiling to
annotate lipid products of HL hydrolysis of VLDL revealed
proportionally more release of monounsaturated (MUFA) and
polyunsaturated (PUFA) fatty acids including OA and PA.
Consistent with this finding, direct OA stimulation of FAO cells
in vitro recapitulated PPARd activation by HL/VLDL, inducing
ADRP expression, while PA had only modest PPARd effects;
stearic acid, which was not released by HL action on VLDL, had
no PPARd effects.
LPL, EL and HL are members of a family of lipases that
hydrolyze lipid substrates like TGs and PLs. Multiple parameters
define the distinct function of these lipases, including their
expression patterns, substrate preferences, catalytic activity,
endogenous inhibitors and cofactors [38]. Despite their critical
role in lipoprotein metabolism, specific links between the action of
these lipases and fatty acid-activated nuclear receptor responses
remain poorly defined. Prior work suggests lipases can induce
PPAR responses, although mainly with selective PPARa activa-
tion. Our group reported that LPL and EL could activate PPARa
through mechanisms involving VLDL and HDL, respectively
[11,12]. Others have shown that LPL-overexpression in cardiac
myocytes also induces PPARa target gene expression [14]. Chawla
et al. reported LPL-mediated PPARd regulation in murine
macrophages, which express lower levels of PPARa [28]. Both
murine and human hepatocytes express PPARa and PPARd,
making HL’s preferential activation of PPARd over PPARa by the
same VLDL substrate noteworthy. VLDL is a TG rich
lipoprotein; PPAR activation using VLDL as a substrate implicates
TG as an important source for PPAR ligands formed by HL-
mediated catalysis. The relative inability of HDL, IDL and LDL to
activate PPAR responses in our experimental models may be a
consequence of the lower TG content of that characterizes these
other lipoprotein classes in vivo. Additional studies will be needed to
determine how other factors such as apolipoprotein composition,
circulating cofactors or other cell surface co-receptors may also
influence lipase-lipoprotein mediated PPAR activation.
LPL, EL and HL can also facilitate lipoprotein transport
independent of their enzymatic activity [34,38]. We demonstrate
that HL-mediated PPARd activation requires active catalysis.
Figure 3. HL/VLDL increases expression of the canonical PPARd target gene, ADRP. (A) HUVEC were infected with adenovirus constructs
expressing GFP or human HL (MOI of 100) in growth medium for 24 hours. The medium was replaced with serum free medium with lipoprotein
stimulation where indicated for an additional 12 hours. RT-PCR results are expressed as relative copy number arbitrary units (AU), as the ratio of ADRP
to 36B4 internal control. *p,.05 vs. GFP. (B) HUVEC were infected as above with adenovirus constructs expressing GFP, HL or catalytically inactive HL
for 24 hours. Cells were then stimulated with VLDL 20 mg/mL for 12 hours in serum free medium and RNA harvested for gene expression analysis.
*p,.05 vs. GFP. ** p,.05 vs. HL. (C) HUVEC were transfected with the indicated siRNA constructs for 24 hours. Following transfection, cells were
infected with adenovirus constructs for 24 hours in HUVEC growth medium. After adenovirus infection, cells were stimulated with VLDL for an
additional 12 hours before harvesting RNA for gene expression analysis. *p,.05 vs. GFP, **p,.05 vs HL. (D) COS-7 cells were transfected with either
the 4 kb-ADRP luciferase reporter, containing the endogenous PPRE from the human ADRP promoter, or the D1-ADRP luciferase reporter, possessing
a point mutation in the PPRE. Where indicated cells were also transfected with pcDNA3 or HL and stimulated with VLDL 50 mg/mL for 12 hours.
Luciferase and b-galactosidase were harvested as before. *p,.05 vs. control **p,.05 vs. control/VLDL.
doi:10.1371/journal.pone.0021209.g003
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e21209Figure 4. HL/VLDL increases expression of PPARd target genes, in vitro and in vivo. (A) Left Panel. FAO hepatoma cells were infected with
adenovirus GFP, adenovirus HL and adenovirus catalytically inactive HL for 24 hours in serum free medium. After 12 hours stimulation with
lipoprotein, RNA was harvested for gene expression analysis and results are expressed as before. *p,.05 vs. GFP. (A) Right Panel. The concentration
dependent effect of VLDL induction of ADRP mRNA in HL-expressing FAO cells is shown. (B) Oil Red O staining. FAO hepatoma cells treated with
adenovirus GFP and HL along with VLDL 50 mg/mL were fixed in paraformaldehyde overnight then stained with Oil Red O to mark neutral lipid
accumulation. Magnification 106. (C) C57BL/6 (8 week, males) were injected by tail vein with adenovirus GPF or human HL constructs, 1610
11 viral
particles, 100 mL volume. Five days following adenovirus infection, plasma was collected pre-heparin and 30 minutes post heparin injection
(intraperitoneal, 200 U) for HL activity and protein expression; mice were euthanized and tissue was harvested for RNA isolation for gene expression
analysis. *p,.05 vs. GFP. RT-PCR results expressed as relative copy number in arbitrary units. (D) C57BL/6 and ob/ob mice (6–8 week, male)
underwent tail vein injection as above. Five days later tissue was harvested for gene expression. *p,.05 vs. GFP. RT-PCR results expressed as relative
copy number in arbitrary units.
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e21209Although a catalytically inactive HL mutant can promote cellular
lipoprotein uptake, it was no longer capable of activating PPARd.
Similarly, a general lipase inhibitor also repressed HL-mediated
PPARd activation. In a TR-FRET ligand displacement assay,
VLDL hydrolysis by HL displaced a fluorescently labeled ligand
within one hour in a VLDL concentration-dependent way.
Although other intracellular enzymes could conceivably metabolize
VLDL following its endocytosis resulting in PPARd activation, the
data presented here argues for hydrolysis of VLDL and release of
metabolites by HL positioned on the cell surface as a major
contributor to PPAR activation. Together these results suggest
specific products of HL catalysis of VLDL may account for PPARd
activation.
Metabolite profiling using liquid chromatography coupled with
mass spectrometry (LC/MS) is a robust method for annotating
lipid metabolites produced by enzymes in complex biological
systems [37,39]. By applying this unbiased strategy to analyze
lipids generated by HL-mediated hydrolysis of VLDL, specific
molecules released by HL/VLDL were identified, including ones
that could replicate HL/VLDL/PPARd effects. Several new
insights have emerged using this approach. First, VLDL hydrolysis
by HL liberated OA and PA at micromolar concentrations, levels
that overlap the concentrations needed for PPAR activation, as
determined in concurrent PPAR transactivation assays. Second,
other FAs including linolenic, arachidonic, eicosapentaenoic, and
docosohexaenoic acid were also released by HL, but did not
stimulate PPAR transactivation, at least within this system. Third,
the HL depleted TG levels of VLDL more than PLs, further
demonstrating HL’s important TG hydrolase function and
highlighting the role of TG as a substrate in HL-mediated PPARd
activation. It will be of interest to apply this system to investigate
the lipid metabolites generated by LPL and EL, which are also
relevant for isotype specific PPAR responses.
Our finding here that OA is a major FA product of HL lipolysis
that can activate PPARd aligns with several recent reports in the
literature. Sanderson et al. found that OA activates PPARd, not
PPARa responses in liver. In those studies the source of OA
production was not explored [40]. Our data identifies HL as a
specific pathway relevant for hepatocytes that can generate OA
from VLDL, thus offering a direct link between hepatic lipid
metabolism and PPARd activation via HL-generated OA. Of
note, the hydrophobic nature of FAs liberated by HL requires
cytosolic chaperones such as fatty acid binding proteins (FABPs) to
facilitate FA delivery to the nucleus. In this regard, Tan et al.
reported that FABP5 binds OA and translocates this FA to the
nucleus where it interacts with PPARd, thereby promoting
keratinocyte differentiation [41]. By integrating unbiased lipopro-
tein/HL/PPAR activation assays, cell biology studies, and LC/
MS analysis of HL lipolytic reactions, the data provided here
converge with these observations using completely different
approaches. Collectively, these findings suggest a model involving
integrated extracellular to intracellular to nuclear metabolic
pathways that determine specific transcriptional responses.
Similar, but distinct pathways may exist for other nuclear
receptors as defined by variables of lipoprotein substrates, lipases,
metabolites, surface receptors and/or FABPs.
Lipolytic mechanisms that direct specific PPAR isotype
activation suggests new ways to consider how lipid metabolism
may couple to transcriptional and cellular responses. Genetic and
Figure 5. Global metabolite profiling identifies specific unsaturated FAs generated by HL hydrolysis of VLDL that activate PPAR
transcriptional responses. (A) Left Panel. Negative ionization mode LC/MS analysis of lipid extracts from HL/VLDL treatment group demonstrated
significant increases in levels of long chain fatty acids including palmitic (C16:0), palmitoleic (C16:1), oleic (C18:1), linoleic (C18:2), linolenic (C18:3),
arachidonic (C20:4), eicosapentaenoic (C20:5) and docosohexaenoic (C22:6) acid. Absolute nanomoles of fatty acid were calculated using the
integrated ion intensity of the internal standard C
13 oleic acid. Each experimental condition was performed in triplicate, with results representing the
mean +/2 SD. Right Panel. The absolute fold change for each fatty acid comparing treatment with HL/VLDL vs GFP/VLDL is shown. *p,.05 vs GFP/
VLDL for each fatty acid. (B) COS-7 cells were transfected with PPARd-LBD and stimulated with the fatty acids fatty acids indicated. Results expressed
as the percent of maximal LBD activation measured with PPARd synthetic agonist GW501516. *p,.05 vs control. (C) FAO cells were treated with
indicated concentrations of fatty acid in media with 1% BSA, BSA control or the PPARd synthetic agonist GW501516 at maximal concentration.
Following stimulation RNA was harvested and ADRP expression analyzed by RT-PCR. Results expressed as relative copy number in arbitrary units.
*p,.05 vs BSA and control. **p,.05 vs vehicle.
doi:10.1371/journal.pone.0021209.g005
Table 1. Relative Levels of Representative Lipids Measured by
Metabolite Profiling in Samples with HL:VLDL and GFP:VLDL
a.
Lipid Class HL:VLDL/GFP:VLDL
Phospholipids
C34:1 PC 0.83
C34:2 PC 0.73*
C36:2 PC 0.70*
C36:3 PC 0.66*
TAGs
C48:2 0.34*
C50:2 0.40*
C54:6 0.34*
DAGs
34:1 0.10*
36:2 0.09*
LPCs
C18:1 4.2*
CEs
C18:1 0.97
C18:2 0.52
SM
C16:0 0.81
C16:1 0.89
FFAs
C16:0 (2.1)*
C16:1 (7.7)*
C18:1 (4.6)*
C20:4 (6.1)*
C20:5 (7.0)*
C22:6 (1.1)
aData in parentheses were determined by directly quantifying FA levels using
targeted LC/MS method with internal FA standard. TAGs, triacylglycerols;
DAGs, diacylglycerols; LPCs, lysophosphatidic acid; CEs, cholesterol esters; SM,
sphingomyelin; FFAs, free fatty acids. Data represent the mass ion intensity
ratios performed in triplicate for each experimental condition.
*p,.05 for HL:VLDL compared to GFP:VLDL.
doi:10.1371/journal.pone.0021209.t001
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transcriptional regulation of genes involved in lipogenesis and lipid
storage typical of the fed state [42]. In contrast, PPARa controls a
transcriptional program regulating fatty acid b-oxidation and
ketogenesis in the liver as encountered during fasting [43]. The
action of HL to induce PPARd-mediated lipogenesis, including
lipid droplet formation through ADRP, mirrors PPARd effects
seen with synthetic agonists. In the liver, PPAR isotype-specific
responses may also be controlled by metabolites formed by an
opposing pathway of lipid metabolism. In support of this,
Chakravarthy et al. recently identified that fatty acid synthase
(FAS), the rate-limiting enzyme in hepatic de novo lipogenesis, could
generate a specific phosphatidylcholine (GPC 16:0/18:1) capable
of acting as an endogenous hepatic PPARa ligand [10]. The fact
that FAS is the first committed step in palmitic acid biosynthesis
but ultimately fosters FA oxidation through PPARa, while HL, as
a triacylglycerol hydrolase/ phospholipase, functions in lipoprotein
catabolism, but promotes lipogenesis through PPARd suggests
cross-integration of these pathways. Interestingly, levels of this
GPC 16:0/18:1 ligand were modestly reduced in our experiments,
entirely consistent with HL’s phospholipase activity and revealing
other ways through which lipolysis may influence both PPARd
and PPARa responses. Based on the data presented here, it will be
of interest to consider how HL-mediated PPARd activation
influences systemic and hepatic metabolic responses in vivo in
the context of HL and PPARd loss of function in mice and
humans. The recent observation that HL-deficient mice are
protected from diet-induced obesity, display altered energy
substrate utilization and have decreased hepatic steatosis suggests
that HL may play a broader physiologic role in metabolic
adaptations to diet [44]. Further work will be needed to resolve
these issues. The finding that VLDL hydrolysis by HL preferen-
tially activates PPARd provides a new way to reconsider the
functional role of HL and PPARd in the liver and serves as an
example of how cell-based assays can be combined with global
metabolite profiling to explore how lipid metabolism modulates
transcriptional responses.
Supporting Information
Figure S1 Catalytic mutant HL expresses similar pro-
tein levels, but has no triglyceride hydrolase activity.
Left Panel. Control vector, HL or HL catalytic mutant expression
vectors were transfected into COS cells. 24 hours after transfec-
tion, heparin (10 Units) was added to the media to release the
lipase from the cell surface. Both media and cell lysate were
collected for western blot. Right Panel. Media collected from
above was used in triolein activity assay.
(TIF)
Figure S2 SiRNA knockdown of PPARd achieved an 80–
90% knockdown of PPARd expression. HUVEC were
transfected with siRNA for PPARd or a scrambled control.
Following lipoprotein stimulation, RNA was collected for analysis
of gene expression. *p,.05 for siPPARd versus siControl.
(TIF)
Figure S3 Physiologic HDL concentrations activate
PPARd, but not to the same degree as VLDL. COS cells
were transfected with each of the human PPAR-LBDs and
stimulated with HDL (1 mg/mL) as in Figure 1. Data are
presented as relative fold change of luciferase/b-galactosidase.
(TIF)
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